CAR T-Cell Therapy in Autoimmune Disease

To the Editor: In the case series presented by Muller et al. (Feb. 22 issue),(1) CD19-targeting chimeric antigen receptor (CAR) T-cell therapy in patients with systemic lupus erythematosus (SLE) resulted in prompt clinical and serologic remission. In contrast, in patients with Scl70+ systemic sclerosis, serologic remission after CAR T-cell therapy was not as complete. This observation is discrepant with the case of a patient with systemic sclerosis that we recently presented.(2) In the case series, CAR T cells disappeared within a few weeks, whereas the third-generation CD19 CAR T cells that we administered were still detectable at 11 months. It . . .